RxDoctor Payments Data

Qaiser Jawaid, MD

Gastroenterology · O Fallon, MONPI 1437110681

Payments from drug & device makers

$1,435in general payments, 2019–2025

Across 55 payments — averaging $26.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$550
  • Johnson & Johnson$232
  • Ipsen Biopharmaceuticals, Inc$150
  • Intercept Pharmaceuticals, Inc.$141
  • Gilead$139
  • Phathom Pharmaceuticals, Inc.$120
  • plus $102 from 4 others

What the payments were for

  • Food & beverage$1,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,435 in reported general payments places this provider in the 45th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$95,964
Medicare patients
363
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide45$43,476
CreonLipase/Protease/Amylase12$20,695
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates160$10,043
Mesalamine ErMesalamine22$4,939
Sucralfate37$3,436
Pantoprazole Sodium301$3,003
Budesonide EcBudesonide23$2,928
Omeprazole204$2,923
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl224$2,899
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,650
Budesonide DrBudesonide21$2,111
Dexlansoprazole DrDexlansoprazole11$1,934
Duloxetine Hcl13$1,136
Nortriptyline Hcl94$1,130
Famotidine74$968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$550$64,17157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →